Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Explore available award and grant opportunities for fellows-in-training.
Make a choice that matters
The best care starts with the best information. See videos to help answer your questions.
The ACR is accepting applications for mini curriculums, which are educational activities or curriculums to enhance the ACR Core Curriculum Outline.
INFLIXIMAB (Remicade) is a chimeric (part mouse, part human) monoclonal antibody that blocks activity of a key biologic response mediator called “tumor necrosis factor alpha (TNF-α). The action of Remicade is to bind to and neutralize TNF-α on the cell membrane as well as soluble TNF- α and to destroy TNF-α producing cell, thus inhibiting inflammation. Remicade is supplied as a sterile, white lyophilized powder for intravenous infusion.
Patient Medication Guide
Full Prescribing Information
The reconstituted infliximab infusion solution should be prepared by a trained medical professional using aseptic technique by the following procedure:
No physical biochemical compatibility studies have been conducted to evaluate the co-administration of infliximab with other agents. Infliximab should not be infused concomitantly in the same intravenous line with other agents.
Acute infusion reaction or anaphylaxis can occur at any time during the administration of this agent and include flu-like symptoms, headache, dyspnea, hypotension, transient fever, chills, gastrointestinal symptoms, and skin rashes. If patient reports mild reactions (such as flushing, chills, etc.), stop the infusion and assess patient. For more severe reactions (such as hives, difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, fever, chills or anaphylaxis) or where mild reactions persist, stop the infusion and treat the acute reaction. Then notify the supervising provider immediately to coordinate next plan of action. For mild reactions, consider adding additional pre-medications for subsequent doses.
Updated February 2020 - ARP Practice Committee
DISCLAIMER:The information contained in this biologic reference guide is offered solely for purposes of providing health care professionals with a quick and initial reference. Before prescribing or administering any drug contained in this biologic reference guide, health professionals should read the manufacturer’s complete prescribing information in order to be informed of the various clinical considerations to be taken into account. The American College of Rheumatology is providing this information as a benefit and service in furtherance of its educational mission. By providing this information, ACR is not endorsing or recommending any of the listed companies or any of their drugs or other products. The information contained in the biologic reference guides reflect the conclusions of the individual companies and not those of the ACR which specifically disclaims any responsibility or liability for the use of such information and/or for the performance of any of the drugs listed in this biologic reference guide.